Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction.

doi:10.3390/ijms22052268

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction.

International journal of molecular sciences - 25 Feb 2021

Brown Emily E F, Rezaei Reza, Jamieson Taylor R, Dave Jaahnavi, Martin Nikolas T, Singaravelu Ragunath, Crupi Mathieu J F, Boulton Stephen, Tucker Sarah, Duong Jessie, Poutou Joanna, Pelin Adrian, Yasavoli-Sharahi Hamed, Taha Zaid, Arulanandam Rozanne, Surendran Abera, Ghahremani Mina, Austin Bradley, Matar Chantal, Diallo Jean-Simon, Bell John C, Ilkow Carolina S, Azad Taha

Abstract excerpt

Despite sequence similarity to SARS-CoV-1, SARS-CoV-2 has demonstrated greater widespread virulence and unique challenges to researchers aiming to study its pathogenicity in humans. The interaction of the viral receptor binding domain (RBD) with its main host cell receptor, angiotensin-converting enzyme 2 (ACE2), has emerged as a critical focal point for the development of anti-viral therapeutics and vaccines. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Neutralizing

Share to COVID-19 Drug Treatment

Share to Host Microbial Interactions

Share to Protein Interaction Domains and Motifs

Share to Receptors, Virus

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 33668756
DOI: 10.3390/ijms22052268
PMCID: PMC7956771

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction.PMID 33668756Read ↗

Characterization of Critical Determinants of ACE2-RBD InteractionSemantic proximity Read ↗

Utilizing noncatalytic ACE2 protein mutant as a competitive inhibitor to treat SARS-CoV-2 infection.Semantic proximity Read ↗

S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basisSemantic proximity Read ↗

Altered affinity to ACE2 and reduced Fc functional antibodies to SARS-CoV-2 RBD variantsSemantic proximity Read ↗

A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitroSemantic proximity Read ↗

Single point mutations can potentially enhance infectivity of SARS-CoV-2 revealed by in silico affinity maturation and SPR assaySemantic proximity Read ↗

Potential COVID‐19 therapeutic approaches targeting angiotensin‐converting enzyme 2; An updated reviewSemantic proximity Read ↗

Critical ACE2 Determinants of SARS-CoV-2 and Group 2B Coronavirus Infection and Replication.Semantic proximity Read ↗

SARS-CoV-2 Variants of Concern and Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity.Semantic proximity Read ↗

SARS-CoV-2 variant with higher affinity to ACE2 shows reduced sera neutralization susceptibilitySemantic proximity Read ↗

Characterisation of a novel ACE2-based therapeutic with enhanced rather than reduced activity against SARS-CoV2 variantsSemantic proximity Read ↗

Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.